PLoS ONE (Jan 2017)

Metabolomic profiling of amines in sepsis predicts changes in NOS canonical pathways.

  • Abel Tesfai,
  • Niall MacCallum,
  • Nicholas S Kirkby,
  • Hime Gashaw,
  • Nicola Gray,
  • Elizabeth Want,
  • Gregory J Quinlan,
  • Sharon Mumby,
  • James M Leiper,
  • Mark Paul-Clark,
  • Blerina Ahmetaj-Shala,
  • Jane A Mitchell

DOI
https://doi.org/10.1371/journal.pone.0183025
Journal volume & issue
Vol. 12, no. 8
p. e0183025

Abstract

Read online

RationaleNitric oxide synthase (NOS) is a biomarker/target in sepsis. NOS activity is driven by amino acids, which cycle to regulate the substrate L-arginine in parallel with cycles which regulate the endogenous inhibitors ADMA and L-NMMA. The relationship between amines and the consequence of plasma changes on iNOS activity in early sepsis is not known.ObjectiveOur objective was to apply a metabolomics approach to determine the influence of sepsis on a full array of amines and what consequence these changes may have on predicted iNOS activity.Methods and measurements34 amino acids were measured using ultra purification mass spectrometry in the plasma of septic patients (n = 38) taken at the time of diagnosis and 24-72 hours post diagnosis and of healthy volunteers (n = 21). L-arginine and methylarginines were measured using liquid-chromatography mass spectrometry and ELISA. A top down approach was also taken to examine the most changed metabolic pathways by Ingenuity Pathway Analysis. The iNOS supporting capacity of plasma was determined using a mouse macrophage cell-based bioassay.Main resultsOf all the amines measured 22, including L-arginine and ADMA, displayed significant differences in samples from patients with sepsis. The functional consequence of increased ADMA and decreased L-arginine in context of all cumulative metabolic changes in plasma resulted in reduced iNOS supporting activity associated with sepsis.ConclusionsIn early sepsis profound changes in amine levels were defined by dominant changes in the iNOS canonical pathway resulting in functionally meaningful changes in the ability of plasma to regulate iNOS activity ex vivo.